VivoSeq
Psychiatry

Obsessive-Compulsive Disorder

54

Pipeline Programs↗

13

Active Trials↗

28

Companies Involved↗

Obsessive-Compulsive Disorder is a moderately active landscape with 54 programs across 28 companies. The most active players are Novartis, Orexigen Therapeutics, Inc, Institut de Recherches Internationales Servier. 23 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

62/100

Pipeline Velocity

22/100

Mech. Concentration

19/100

Completion Rate

79/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

3 programs

Phase 2O

Orexigen Therapeutics, Inc

1 program

Phase 2Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier

1 program

Phase 2A

Azurity Pharmaceuticals

1 program

Phase 2N

Nobilis Therapeutics Inc.

1 program

Phase 2Regeneron logo

Regeneron

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

98%

Small molecule

56 of 57 classified programs — the dominant modality here.

2%ALL OTHERSMonoclonal antibody12%

Small molecule leads; the ring shows all 57 classified programs, each share of the total. Modality classified for 100% of 57 pipeline programs.

Analysis

Trial Status

94

clinical trials

Completed59 · 63%
Terminated11 · 12%
Recruiting9 · 10%
Unknown status6 · 6%
Withdrawn5 · 5%
Active, not recruiting3 · 3%
Other1 · 1%

Clinical Trials

Trial Activity

94 trials

Safety and Efficacy of Pramipexole Treatment in Resistant Obsessive-Compulsive Disorder (OCD)
Recruiting·—·Phase 2·NCT06611592·48 enrolled
Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.
Recruiting·—·Phase 1·NCT07347405·30 enrolled
Pragmatic Trial of Obsessive-compulsive Disorder
Recruiting·SShanghai Mental Health Center·Phase 2·NCT04539951·1,600 enrolled
Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive Disorder
Recruiting·SSeverance Hospital·N/A·NCT02431845·200 enrolled
Effects of Psilocybin in Obsessive Compulsive Disorder
Recruiting·JJohns Hopkins University·Phase 1·NCT05546658·30 enrolled
Neural Mechanisms of Response Inhibition Training for Obsessive-Compulsive Disorder and Related Conditions
Recruiting·University of Wisconsin, Milwaukee·Preclinical·NCT05377125·118 enrolled
Explore Neural Mechanism of Obsessive-Compulsive Disorder (OCD) by Intervention of Repetitive Transcranial Magnetic Stimulation With Symptom Provocation
Recruiting·TTaipei Veterans General Hospital, Taiwan·Preclinical·NCT07587112·96 enrolled
Effects of Aerobic Exercise on Obsessive-Compulsive Disorder Symptoms and Cognitive Flexibility
Recruiting·YYale University·Preclinical·NCT07103902·50 enrolled
Leveraging Machine Learning Approaches to Understand Mechanisms of Exposure Therapy in Real-World Settings
Recruiting·MMclean Hospital·Preclinical·NCT06173752·400 enrolled
A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder
Active, not recruiting·UUniversity of Chicago·Phase 2·NCT05624528·49 enrolled
Using Personalized Assessments in the Treatment of Childhood OCD
Active, not recruiting·JJohns Hopkins University·Preclinical·NCT06407648·30 enrolled
Efficacy and Underlying Mechanisms of Group-Based Natural Psychotherapy for Anxiety Disorder
Active, not recruiting·BBeijing HuiLongGuan Hospital·Preclinical·NCT07518264·60 enrolled
Valbenazine in Obsessive Compulsive Disorder
Not yet recruiting·UUniversity of Chicago·Phase 2·NCT07111988·30 enrolled
Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder
Completed·MMontefiore Medical Center·Phase 4·NCT00211744·24 enrolled
N-acetylcysteine (NAC) for Pediatric Obsessive-Compulsive Disorder
Completed·YYale University·Phase 2·NCT01172275·11 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)